Get the Stockscreener App
1,020.84
7.79%
-86.28
After Hours:
1021.70
0.86
+0.08%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,020.84, with a volume of 7.70M.
It is down -7.79% in the last 24 hours and down -1.98% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,107.12
Open:
$1065.5
24h Volume:
7.70M
Relative Volume:
2.13
Market Cap:
$913.67B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
50.49
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-0.32%
1M Performance:
-1.98%
6M Performance:
+33.28%
1Y Performance:
+21.21%
1-Day Range:
$1,005.83
$1,075.00
1-Week Range:
$993.58
$1,114.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,020.84 | 990.89B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
237.79 | 564.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.02 | 383.72B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
119.75 | 293.70B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
153.95 | 293.40B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY - Business Wire
Eli Lilly (LLY) Price Target Raised by JP Morgan to $1,300 | LLY Stock News - GuruFocus
Eli Lilly Just Delivered Fantastic News to Shareholders - The Motley Fool
Eli Lilly's 2026 Outlook Push Back Demand Fears: Analyst - Benzinga
P/E Ratio Insights for Eli Lilly and Co - Benzinga
Trump administration to launch TrumpRx website for discounted drugs - Indianapolis Business Journal
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today - Finviz
Novo Will Never Beat Lilly. Why Does It Have To? - BioSpace
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
Cantor Fitzgerald Raises Price Target for Eli Lilly (LLY) to $12 - GuruFocus
Eli Lilly Beats Q4 Estimates But Shares Slide: Analyst Expects 'Clear Runway Into Next Decade' - Benzinga
Why Eli Lilly Stock Just Dropped - The Motley Fool
Eli Lilly: Why Investors Are Rewarding It as Novo Slips - Investing.com
Eli Lilly plans $3.5B weight-loss drug factory - Supply Chain Dive
Novo and Lilly both see price cuts as helpful for long-term gain - statnews.com
Hims & Hers Health launched a generic version of the Wegovy weight-loss drug, causing declines in the share prices of Novo-Nordisk A/S and Eli Lilly and Co. - 富途牛牛
LLY Stock: Recent Developments and Market Impact - GuruFocus
Leerink Partners Adjusts Price Target on Eli Lilly to $1,296 From $1,234, Maintains Outperform Rating - marketscreener.com
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles - Finviz
Expert Outlook: Eli Lilly and Co Through The Eyes Of 15 Analysts - Benzinga
Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript - Insider Monkey
Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly - Reuters
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $1,205 From $985, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts PT on Eli Lilly and Co. to $1,280 From $1,200, Maintains Overweight Rating - marketscreener.com
Eli Lilly and Co. blood drive beats goal - reporter.net
Analyst recommendations: Corteva, Snap, Alphabet, Eli Lilly, PayPal, Qualcomm… - marketscreener.com
Eli Lilly Shares Boosted by GLP-1s - Investing.com
Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen - Chartmill
Eli Lilly’s Blockbuster Quarter Propelled by Weight-Loss Drug Dominance - AD HOC NEWS
Eli Lilly (LLY) Skyrockets as Profits Soar 95% - Finviz
Weight Loss Drug Giant Eli Lilly’s Market Cap Surges Nearly $100 Billion, Accelerating Expansion into New Gene Therapy Sector - NAI500
Is Eli Lilly (LLY) Still Attractive After Obesity Drug Headlines And A US$1,107 Share Price? - Yahoo Finance UK
Eli Lilly Stock Notches Best Day In 9 Months: Touts $50 Medicare For Obesity Drugs As ‘Compelling Value Proposition’ After Q4 Beat - Stocktwits
Eli Lilly (LLY) Reports Strong Q4 2025 Financial Performance - GuruFocus
LLY Stock Surges On Q4 Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook - Stocktwits
Eli Lilly Earnings: Revenue Increases Reflect Global Demand for Oral Obesity Therapies - Morningstar
Eli Lilly and Co (LLY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Eli Lilly's Dominant Diabetes and Obesity Portfolio Underpins a Wide Moat - Morningstar
Eli Lilly and Co (LLY) Q4 2025 Earnings Call Highlights: Record - GuruFocus
Eli Lilly Invests $3.5 Billion in Pennsylvania for Weight-Loss Therapies - StocksToTrade
Patent Moat + Continuous New Drug Approvals: Eli Lilly and Co Reinforces Its Leadership in the Weight Loss Drug Market with Full-Year Guidance - 富途牛牛
Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026 - Fierce Pharma
Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge - MSN
Lilly and Novo Whipsaw Wall Street With Split in Obesity Outlook - Bloomberg.com
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk - Benzinga
Novo’s Wegovy Pill Success Is ‘Good News’ for Orforglipron, Lilly Execs Say - BioSpace
Lilly runs up stock market on better estimates than Novo Nordisk for anti-obesity drugs - Il Sole 24 ORE
Eli Lilly bets on weight loss drug growth as Novo Nordisk stumbles - Dallas News
Eli Lilly stock rises as Deutsche Bank reiterates Buy rating on strong 2026 guidance - Investing.com
Research Alert: CFRA Raises Rating On Shares Of Eli Lilly And Company To Strong Buy From Buy - 富途牛牛
Eli Lilly Investing $3.5 Billion in Pennsylvania Site - AdvancedManufacturing.org
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):